Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Vu Khanh An Le"'
Autor:
Hai Trieu Ly, Vu Khanh Trang Le, Van Minh Le, Cong Sanh Phan, Chau Tuan Vo, Minh Ly Nguyen, Thi Anh Dao Phan
Publikováno v:
Vietnam Journal of Science, Technology and Engineering, Vol 64, Iss 1 (2022)
This study screened phytochemicals to determine their total polyphenols content (TPC) by Folin-Ciocalteu reagents and to evaluate antioxidant activity using DPPH scavenging, ABTS cation decolorization, and reducing power assays of various extracts of
Externí odkaz:
https://doaj.org/article/4ff45a142a004e519c23cf362fd07fbe
Publikováno v:
GSC Advanced Research and Reviews. 13:181-187
Purpose:Traumatic cervical spondyloptosis is a rare clinical pathology that often causes complete paralysis. When a patient presents neurologically intact or incomplete paralysis, the management becomes more complicated. Preservation of neural functi
Autor:
Ngoc Bao Tri Pham, Thi Ngoc Ha Vo, Thi Thu Thao Bui, Thanh Tam Nguyen, Minh Ly Nguyen, Vinh Quang Dang, Nguyen Gia Linh Phan, Quoc Vinh Tran, Vu Khanh Trang Le, Cong Khanh Tran
Publikováno v:
Journal of Nanoscience and Nanotechnology. 21:1598-1605
Ag/SiO2 colloidal nanocomposites (NCs) were prepared through the semi-continuous chemical reduction of silver ions on a silica surface; NaBH4 was used as a primary reducing agent, while carboxymethyl cellulose (CMC) served as a secondary reductant an
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Anh Hoang Dao, Vu Khanh Hoa Le, Duy Hieu Truong, Thi Phuong Dung Pham, Tung Thanh Pham, Tuan Hiep Tran
Publikováno v:
Journal of Drug Delivery Science and Technology. 55:101348
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that has been approved for metastatic non-small cell lung cancer and highly aggressive pancreatic cancer. Although erlotinib contributes progressively to cancer treatment, there is sti